Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT00997334
Title Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors David M. Jackman, MD
Age Groups: adult
Covered Countries USA

No variant requirements are available.